MX2015016995A - Formulacion compuesta en capsula farmaceutica que comprende tadalafil y tamsulosina. - Google Patents

Formulacion compuesta en capsula farmaceutica que comprende tadalafil y tamsulosina.

Info

Publication number
MX2015016995A
MX2015016995A MX2015016995A MX2015016995A MX2015016995A MX 2015016995 A MX2015016995 A MX 2015016995A MX 2015016995 A MX2015016995 A MX 2015016995A MX 2015016995 A MX2015016995 A MX 2015016995A MX 2015016995 A MX2015016995 A MX 2015016995A
Authority
MX
Mexico
Prior art keywords
composite formulation
tamsulosin
tadalafil
capsule composite
pharmaceutical capsule
Prior art date
Application number
MX2015016995A
Other languages
English (en)
Inventor
Yong Il Kim
Jae Hyun Park
Jong Soo Woo
Caleb Hyungmin Park
Young-Su Yoon
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of MX2015016995A publication Critical patent/MX2015016995A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se divulga una formulación compuesta en cápsula para prevenir o tratar la disfunción eréctil y la hiperplasia prostática benigna que comprende tadalafil y tamsulosina, y un método de preparación de la misma. La formulación compuesta en cápsula de la presente invención permite la separación completa de los dos ingredientes farmacéuticamente activos y reduce al mínimo la reactividad entre los ingredientes activos, y por lo tanto proporciona una excelente estabilidad del producto al paso del tiempo, aumentando al máximo así los efectos terapéuticos de los mismos.
MX2015016995A 2013-06-28 2014-06-30 Formulacion compuesta en capsula farmaceutica que comprende tadalafil y tamsulosina. MX2015016995A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20130076073 2013-06-28
PCT/KR2014/005813 WO2014209087A1 (en) 2013-06-28 2014-06-30 Pharmaceutical capsule composite formulation comprising tadalafil and tamsulosin

Publications (1)

Publication Number Publication Date
MX2015016995A true MX2015016995A (es) 2016-04-25

Family

ID=52142324

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015016995A MX2015016995A (es) 2013-06-28 2014-06-30 Formulacion compuesta en capsula farmaceutica que comprende tadalafil y tamsulosina.

Country Status (12)

Country Link
EP (1) EP3013327A4 (es)
KR (1) KR102246657B1 (es)
CN (1) CN105338970B (es)
AU (1) AU2014299447B2 (es)
BR (1) BR112015032728A2 (es)
EA (2) EA033983B1 (es)
HK (1) HK1219889A1 (es)
MX (1) MX2015016995A (es)
PH (1) PH12015502721B1 (es)
RU (1) RU2672573C2 (es)
UA (1) UA118110C2 (es)
WO (1) WO2014209087A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY190876A (en) * 2015-01-28 2022-05-13 Hanmi Pharm Ind Co Ltd Composite capsules comprising raloxifene, and vitamin d or its derivatives
KR20160100570A (ko) * 2015-02-16 2016-08-24 한미약품 주식회사 탐수로신 염산염 함유 서방성 과립을 포함하는 경구용 약제학적 제제
KR20170113459A (ko) * 2016-03-31 2017-10-12 한미약품 주식회사 타다라필 및 암로디핀 함유 고형 복합제제
BR112018069852A2 (pt) * 2016-03-31 2019-01-29 Hanmi Pharm Ind Co Ltd formulação compósita de cápsula e método para preparar a formulação compósita de cápsula
KR101879133B1 (ko) * 2017-07-11 2018-07-17 (주)동구바이오제약 비뇨기 질환 예방 또는 치료용 제제 및 이의 제조방법
KR102169926B1 (ko) * 2018-01-12 2020-10-26 주식회사 종근당 탐스로신과 타다라필을 포함하는 약제학적 조성물
KR20210081113A (ko) 2019-12-23 2021-07-01 한미약품 주식회사 탐수로신 및 타다라필을 포함하는 경구용 복합제제 및 그 제조방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7670612B2 (en) * 2002-04-10 2010-03-02 Innercap Technologies, Inc. Multi-phase, multi-compartment capsular delivery apparatus and methods for using same
US20100221321A1 (en) * 2003-02-27 2010-09-02 Innercap Technologies, Inc. Apparatus And Methods For Delivering A Plurality Of Medicaments For Management Of Co-Morbid Diseases, Illnesses Or Conditions
KR100706036B1 (ko) 2005-04-04 2007-04-11 대화제약 주식회사 염산 탐술로신 서방성 정제 및 그의 간단한 제조방법
DE102005016981A1 (de) * 2005-04-13 2006-10-19 Bayer Healthcare Ag Kombination zur Therapie bei benigner Prostatahyperplasie
KR100795419B1 (ko) * 2006-01-03 2008-01-17 (주)네오메딕스 암로디핀 및 아스피린을 함유하는 약학 제제
EP2106792A1 (en) * 2008-04-02 2009-10-07 Pelvipharm Use of a combination of udenafil and alfuzosin or oxybutynin for the treatment of overactive bladder
KR101861307B1 (ko) * 2011-10-13 2018-07-06 한미약품 주식회사 정제를 포함하는 경질 캡슐 복합 제형

Also Published As

Publication number Publication date
RU2016102605A (ru) 2017-08-02
PH12015502721A1 (en) 2016-03-14
CN105338970A (zh) 2016-02-17
CN105338970B (zh) 2019-07-09
AU2014299447B2 (en) 2019-01-17
RU2016102605A3 (es) 2018-05-15
RU2672573C2 (ru) 2018-11-16
EP3013327A4 (en) 2016-11-16
EA039091B1 (ru) 2021-12-02
EP3013327A1 (en) 2016-05-04
WO2014209087A1 (en) 2014-12-31
EA201690100A1 (ru) 2016-04-29
AU2014299447A1 (en) 2015-12-17
EA201992020A1 (ru) 2020-01-16
BR112015032728A2 (pt) 2017-07-25
KR102246657B1 (ko) 2021-04-30
HK1219889A1 (zh) 2017-04-21
EA033983B1 (ru) 2019-12-17
PH12015502721B1 (en) 2016-03-14
UA118110C2 (uk) 2018-11-26
KR20150002550A (ko) 2015-01-07

Similar Documents

Publication Publication Date Title
PH12015502721A1 (en) Pharmaceutical capsule composite formulation comprising tadalafil and tamsulosin
MX2022001755A (es) Compuestos de dinucleotidos ciclicos y metodos de uso.
ZA201902053B (en) Pharmaceutical composition
MX2021004639A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos.
MA40539A (fr) Procédés de formulation de compositions de conjugués anticorps-médicaments
IN2014MU00303A (es)
PH12016501841A1 (en) Immunosuppressant formulation
MX2018012618A (es) Composiciones farmaceuticas orales de mesalazina.
MX2017006437A (es) Compuestos espiroisoquinolin-1,4'-piperidinicos con actividad multimodal contra el dolor.
EA036036B1 (ru) Композиции, содержащие циклоспорин
PH12020551018A1 (en) Oral delivery of glp-1 peptide analogs
PH12018500814A1 (en) Oxadiazaspiro compounds for the treatment of drug abuse and addiction
EP4219525A3 (en) Foxm1-derived peptide, and vaccine including same
SG10201900933YA (en) Koc1-derived peptide and vaccine including same
SG10201900879PA (en) Cdca1-derived peptide and vaccine containing same
MX2021016053A (es) Formulaciones de espuma rectal.
MX2021015026A (es) Peptido derivado de urlc10 y vacuna que lo contiene.
PH12020500510A1 (en) Prophylactic and/or therapeutic agent for diseases involving ido expression
TH165164A (th) สูตรผสมเชิงประกอบทางเภสัชกรรมของแคปซูลที่ประกอบรวมด้วยทาดาลาฟิล และแทมซูโลซิน
GB2541348A (en) Clopidogrel for use in the treatment of benign prostatic hyperplasia
TH165164B (th) สูตรผสมเชิงประกอบทางเภสัชกรรมของแคปซูลที่ประกอบรวมด้วยทาดาลาฟิล และแทมซูโลซิน
IN2015MU00907A (es)
MY194854A (en) A Pharmaceutical Formulation for Preventing or Treating Hypertension and the Method of Preparation Thereof
UA109242U (uk) Стабільна фармацевтична композиція, що містить інгібітор протеасом

Legal Events

Date Code Title Description
FG Grant or registration
GD Licence granted